Analyst: Bavarian Nordic RSV partnership could be first of many

Bavarian Nordic’s partnership with Nuance Pharma, which was announced on Monday, is important and very positive for the Danish firm, says Analyst Søren Lønfoft Hansen, mentioning that this might be the first of many.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
by marketwire, translated by daniel pedersen

On Monday, Bavarian Nordic signed a very important and positive deal with Nuance Pharma, says Senior Equity Analyst at Sydbank Søren Løntoft Hansen. He has kept an eye on Bavarian’s stock following the news, reporting that the Danish company has had a markedly better start than the general market today.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading